Virchows Archiv

, Volume 456, Issue 1, pp 39–44 | Cite as

DcR1 expression in endometrial carcinomas

  • Jordi Tarragona
  • Nuria Llecha
  • Maria Santacana
  • Susana Lopez
  • Sonia Gatius
  • David Llobet
  • Xavier Dolcet
  • Victor Palomar-Asenjo
  • Francisco Javier Gonzalez-Tallada
  • Xavier Matias-Guiu
Original Article
First Online:
Received:
Revised:
Accepted:

Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which mediates apoptosis by the extrinsic pathway. Up-regulation of decoy receptors, DcR1 and DcR2, may result in diminished binding of TRAIL to their functional receptors. DcR1 expression was assessed in normal endometrial tissue (NE) and endometrial carcinoma (EC) samples by immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (PCR). IHC was performed in two tissue microarrays; one composed of 80 samples of NE and a second one constructed from paraffin-embedded blocks of 62 EC. For quantitative real-time RT-PCR analysis, RNA was obtained from 19 NE and 28 EC samples using Trizol®. mRNA expression of DcR1 was assessed with Taqman®-based assays in an Abi-Prism 700 SDS. Results were correlated with stage, histological type, and grade. By IHC, cytoplasmic expression of DcR1 was frequently seen in NE (79.6%) and varied according to the menstrual cycle. Positive DcR1 immunostaining was also detected in EC (98.1% of the cases) without any specific statistical association with histological type, grade, and stage. By quantitative real-time PCR, all NE had similar levels of DcR1expression (0.8–1.7 RQ), which were considered the basal levels of DcR1 expression in NE. Increased DcR1 expression (≥5-fold higher than the basal levels) was detected in 13 of 28 EC (46.4%). High DcR1 expression levels were found in ECs of different stages: IA, four of 12 (33%); IB, two of four (50%); IC, four of six (66%); and IIA and IIB three of six (50%). Results suggest that DcR1 expression occurs in a subset of EC and may contribute to resistance to TRAIL-induced apoptosis.

Keywords

Endometrial carcinoma DcR1 Tissue microarray Apoptosis resistance 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest statement

We declare that we have no conflict of interest.

References

  1. 1.
    Catasus L, Matias-Guiu X, Machín P et al (1998) BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium. Lab Invest 78:1439–1444PubMedGoogle Scholar
  2. 2.
    Pallares J, Martínez-Guitarte JL, Dolcet X et al (2004) Abnormalities in NF-κB family and related proteins in endometrial carcinoma. J Pathol 204:569–577CrossRefPubMedGoogle Scholar
  3. 3.
    Pallares J, Martínez-Guitarte JL, Dolcet X et al (2005) Survivin expression in endometrial carcinoma. Int J Gynecol Pathol 24:247–253CrossRefPubMedGoogle Scholar
  4. 4.
    Dolcet X, Llobet D, Pallares J et al (2005) FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 85:885–894CrossRefPubMedGoogle Scholar
  5. 5.
    Gupta S (2003) Molecular signaling in death receptor and mitochondrial pathways of apoptosis. Int J Oncol 22(1):15–20PubMedGoogle Scholar
  6. 6.
    Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11(9):372–377CrossRefPubMedGoogle Scholar
  7. 7.
    Thorburn A (2004) Death receptor induced cell killing. Cell Signal 16:139–144CrossRefPubMedGoogle Scholar
  8. 8.
    Zörnig M, Hueber A, Baum W et al (2001) Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551:F1–F37PubMedGoogle Scholar
  9. 9.
    Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228–237CrossRefPubMedGoogle Scholar
  10. 10.
    Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–428CrossRefPubMedGoogle Scholar
  11. 11.
    Igney FH, Krammer PH (2003) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288CrossRefGoogle Scholar
  12. 12.
    Kaufmann SH, Vaux DL (2003) Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22:7414–743CrossRefPubMedGoogle Scholar
  13. 13.
    Pallares J, Llobet D, Santacana M et al (2009) CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 174:287–296CrossRefPubMedGoogle Scholar
  14. 14.
    Pallares J, Velasco A, Eritja N et al (2008) Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 21:691–699CrossRefPubMedGoogle Scholar
  15. 15.
    Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Arguelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32:569–577CrossRefPubMedGoogle Scholar
  16. 16.
    Catasus L, Machin P, Matias-Guiu X et al (1998) Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 29:1160–1164CrossRefPubMedGoogle Scholar
  17. 17.
    Kanamori Y, Kigawa J, Itamochi H et al (2001) Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7:892–895PubMedGoogle Scholar
  18. 18.
    Bussaglia E, del Rio E, Matias-Guiu X et al (2000) PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31:312–317CrossRefPubMedGoogle Scholar
  19. 19.
    Tashiro H, Blazes MS, Wu R et al (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935–3940PubMedGoogle Scholar
  20. 20.
    Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669–10673CrossRefPubMedGoogle Scholar
  21. 21.
    Velasco A, Bussaglia E, Pallares J et al (2006) PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37:1465–1472CrossRefPubMedGoogle Scholar
  22. 22.
    Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193:193–9CrossRefPubMedGoogle Scholar
  23. 23.
    Machin P, Catasus L, Pons C, Muñoz J, Matias-Guiu X, Prat J (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Human Pathol 33:206–212CrossRefGoogle Scholar
  24. 24.
    Tashiro H, Isacson C, Levine R et al (1997) p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 150:177–185PubMedGoogle Scholar
  25. 25.
    Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Human Pathol 26:1268–1274CrossRefGoogle Scholar
  26. 26.
    Llobet D, Eritja N, Encinas M et al (2008) CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 27:2513–24CrossRefPubMedGoogle Scholar
  27. 27.
    Clancy L, Mruk K, Archer K et al (2005) Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102:18099–18104CrossRefPubMedGoogle Scholar
  28. 28.
    Mérino D, Lalaoui N, Morizot A et al (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046–7055CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jordi Tarragona
    • 1
  • Nuria Llecha
    • 1
  • Maria Santacana
    • 1
  • Susana Lopez
    • 1
  • Sonia Gatius
    • 1
  • David Llobet
    • 1
  • Xavier Dolcet
    • 1
  • Victor Palomar-Asenjo
    • 1
  • Francisco Javier Gonzalez-Tallada
    • 2
  • Xavier Matias-Guiu
    • 1
  1. 1.Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de VilanovaUniversity of Lleida IRBLLEIDALleidaSpain
  2. 2.Department of Gynecology, Hospital Universitari Arnau de VilanovaUniversity of Lleida, IRBLLEIDALleidaSpain

Personalised recommendations